Xeris Biopharma achieved record quarterly revenue of $85.8 million, driven by a 100% increase in Recorlev sales. The company transitioned to profitability in Q4 with a net income of $11.1 million and significantly improved its Adjusted EBITDA, ending the year as a self-funding entity.

Xeris Biopharma generated $74380000 in total revenue for Q3 2025, driven by strong product sales, particularly Recorlev. The company reported positive net income of $621000 and operating income of $6731000, with growth across key products and improved gross margins.

Xeris Biopharma achieved record financial results in Q2 2025, with total revenue increasing by 49% year-over-year to $71.5 million, primarily fueled by a 136% surge in Recorlev revenue. The company also raised its full-year 2025 revenue guidance, reflecting strong patient demand and confidence in continued growth.

Xeris Biopharma reported a strong start to 2025 with record first-quarter revenue of over $60 million, a 48% year-over-year increase, driven by significant growth in Recorlev revenue. The company also tightened its full-year total revenue guidance.

Xeris Biopharma reported a record Q4 2024 with total revenue of $60.10 million, reflecting a 35.4% year-over-year increase. Net loss improved significantly to $5.11 million from $13.39 million in Q4 2023. The company generated positive cash flow of $2 million and posted an Adjusted EBITDA of $8.3 million. Strong growth in Recorlev, which saw a 131% YoY increase in revenue, contributed significantly to the performance. The company ended the quarter with $71.62 million in cash, maintaining a strong financial position.

Xeris Biopharma reported a record-breaking quarter with total revenue of $54 million, driven by strong demand for Recorlev and Gvoke. Product revenue increased 27% year-over-year, marking the 12th consecutive quarter of over 20% growth. The company raised its full-year revenue guidance to $198-$202 million.

Xeris Biopharma reported a strong second quarter in 2024, achieving $48.1 million in total revenue, including record product revenue of $46.5 million. Total revenues increased 18% over the prior quarter and 26% over the same period prior year. The company is tightening its full-year 2024 revenue guidance to $190M-$200M and year-end cash balance to $60M-$75M.

Xeris Biopharma reported a 22% increase in total revenue to $40.6 million for Q1 2024 compared to Q1 2023. The growth was primarily driven by Recorlev, Keveyis and Gvoke sales. The company tightened its full-year 2024 revenue guidance to $175 million - $200 million.

Xeris Biopharma reported a strong Q4 2023 with a 34% increase in total revenue, reaching over $44 million, and achieved cash flow positive status with over $6 million. The company ended the year with over $72 million in cash, cash equivalents, and short-term investments. They also refinanced their Hayfin term loan and entered into a worldwide license agreement for XeriJect® formulation of teprotumumab.

Xeris Biopharma reported record revenue of $48.3 million for the third quarter of 2023, a 27% increase from the previous quarter and a 63% increase from the same period last year. The company has tightened its full-year 2023 revenue guidance to $160 million - $165 million and is on track to achieve cash flow breakeven in the fourth quarter.

Xeris Biopharma reported record revenue of $38.0 million for Q2 2023, a 50% increase compared to the same period last year. The company is tightening its full-year 2023 guidance, expecting total net revenue between $145M and $165M and anticipates reaching cash flow breakeven by the end of 2023.

Xeris Biopharma reported a strong start to 2023, achieving record total revenue of $33.2 million, a 50% increase compared to Q1 2022. The company ended the quarter with $95.1 million in cash, cash equivalents, and short-term investments and reaffirmed its 2023 revenue and cash guidance.

Xeris Biopharma reported a strong fourth quarter in 2022, with a 52% increase in net product revenue compared to Q4 2021. The company achieved full-year net product revenue growth of 38% on a pro forma basis and ended the year with $122.0 million in cash, cash equivalents, and short-term investments. Xeris also provided 2023 revenue guidance of $135M-$165M and anticipates cash flow breakeven in Q4 2023.

Xeris Biopharma reported a strong third quarter with record net product revenue of $29.6 million, a 17% increase from Q2 2022 and a 31% increase from the same period last year on a pro forma basis. The company also raised its year-end cash balance guidance to $110-$120 million and reaffirmed its full-year total net product revenue guidance to $105M-$110M.

Xeris Biopharma reported record net product revenue of $25.3 million for the second quarter of 2022, a 15% increase from Q1 2022 and a 34% increase from the same period last year on a pro forma basis. The company ended the quarter with $111.6 million in cash, cash equivalents, and short-term investments. Xeris Biopharma reaffirmed its full-year total net product revenue guidance of $105 million to $120 million.

Xeris Biopharma reported a strong first quarter with a 33% increase in net product revenue on a pro forma basis, driven by higher sales of Gvoke, Keveyis, and the launch of Recorlev. The company ended the quarter with $132.1 million in cash and cash equivalents and affirmed its 2022 revenue and year-end cash guidance.

Xeris Biopharma reported a significant increase in net product revenues for both the fourth quarter and full year 2021, driven by increased demand and the acquisition of Keveyis. The company's cash position remains strong, and they anticipate achieving cash flow breakeven by year-end 2023.

Xeris Biopharma reported strong growth in Q3 2021, with pro forma net sales of $22.5 million driven by Gvoke and Keveyis. The company completed the Strongbridge acquisition and is on track to realize $50 million in synergies. They anticipate year-end cash, cash equivalents, and investments of approximately $100 million.